Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Ariel Global Fund Ariel Investments, LLC | “We re-initiated a position in Bristol-Myers Squibb Company (BMY), a global leader in oncology and cardiovascular treatments anchored by flagship therapies such as Opdivo and Eliquis. While upcoming patent expirations pose a challenge, we believe new therapies and pipeline opportunities could offer meaningful upside. Recent market weakness following a trial setback created an attractive entry point in shares ahead of key clinical readouts in stroke prevention and atrial fibrillation. BSD Analysis: Bristol-Myers is navigating a patent-expiration valley with a pipeline that must prove its depth. Cash flows from legacy blockbusters fund aggressive business development. Oncology and immunology remain core strengths. Investors worry about revenue cliffs, but that risk is well-telegraphed and partially priced. Execution on newer assets is the key variable. Capital allocation discipline matters more than discovery hype here. The dividend anchors valuation during uncertainty. If pipeline assets scale, sentiment improves fast. This is big pharma at an inflection, not a terminal decline.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
